Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Inspire Investing LLC grew its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 40.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,216 shares of the biotechnology company’s stock after buying an additional 2,936 shares during the period. Inspire Investing LLC’s holdings in United Therapeutics were worth $3,254,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. ClariVest Asset Management LLC grew its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth approximately $32,000. Innealta Capital LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $33,000. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,522 shares of company stock valued at $37,671,474. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. Oppenheimer lifted their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. LADENBURG THALM/SH SH cut shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, UBS Group increased their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Price Performance

UTHR opened at $342.59 on Thursday. The company has a market capitalization of $15.24 billion, a price-to-earnings ratio of 16.20, a PEG ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $366.08. The business’s fifty day simple moving average is $337.74 and its 200-day simple moving average is $289.59.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.24 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.